These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35698895)

  • 21. Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab.
    Shamsudeen I; McCrindle BW; Hegele RA
    JCEM Case Rep; 2023 May; 1(3):luad058. PubMed ID: 37305647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
    Gu J; Kuznik A; Quon P; Chauhan A; Sravya TS; Raal FJ
    Eur J Prev Cardiol; 2023 Nov; 30(17):1874-1880. PubMed ID: 37314419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
    Gaudet D; Greber-Platzer S; Reeskamp LF; Iannuzzo G; Rosenson RS; Saheb S; Stefanutti C; Stroes E; Wiegman A; Turner T; Ali S; Banerjee P; Drewery T; McGinniss J; Waldron A; George RT; Zhao XQ; Pordy R; Zhao J; Bruckert E; Raal FJ
    Eur Heart J; 2024 Jul; 45(27):2422-2434. PubMed ID: 38856678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
    Mohamed F; Mansfield BS; Raal FJ
    Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment.
    van den Bosch SE; Corpeleijn WE; Hutten BA; Wiegman A
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia.
    Butt WZ; Yee JK
    Curr Atheroscler Rep; 2022 May; 24(5):379-389. PubMed ID: 35344138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evinacumab in Patients with Refractory Hypercholesterolemia.
    Rosenson RS; Burgess LJ; Ebenbichler CF; Baum SJ; Stroes ESG; Ali S; Khilla N; Hamlin R; Pordy R; Dong Y; Son V; Gaudet D
    N Engl J Med; 2020 Dec; 383(24):2307-2319. PubMed ID: 33196153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience.
    Stefanutti C; Chan DC; Di Giacomo S; Morozzi C; Watts GF
    Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36422519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evinacumab to treat hypercholesterolemia.
    Engler C; Ebenbichler C
    Drugs Today (Barc); 2021 Oct; 57(10):607-619. PubMed ID: 34713869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evinacumab: First Approval.
    Markham A
    Drugs; 2021 Jun; 81(9):1101-1105. PubMed ID: 34003472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New algorithms for treating homozygous familial hypercholesterolemia.
    Tromp TR; Cuchel M
    Curr Opin Lipidol; 2022 Dec; 33(6):326-335. PubMed ID: 36206078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individualized dosing of evinacumab is predicted to yield reductions in drug expenses.
    Ter Heine R; Rongen GA; Roeters van Lennep J; Rutten JHW
    J Clin Lipidol; 2023; 17(3):401-405. PubMed ID: 36967323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
    Kosmas CE; Bousvarou MD; Sourlas A; Papakonstantinou EJ; Peña Genao E; Echavarria Uceta R; Guzman E
    Clin Pharmacol; 2022; 14():49-59. PubMed ID: 35873366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.
    Rosenson RS; Burgess LJ; Ebenbichler CF; Baum SJ; Stroes ESG; Ali S; Khilla N; McGinniss J; Gaudet D; Pordy R
    JAMA Cardiol; 2023 Nov; 8(11):1070-1076. PubMed ID: 37703006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Identifying possible homozygous familial hypercholesterolemia patients: an Italian experts' opinion].
    Bilato C; Zambon A; Pisciotta L; Citroni N; Carubbi F; Zambon S; Zenti MG; Vinci P; Biolo G; Bonomo K; Egalini F; Passaro A; Nascimbeni F; Negri E; D'Addato S; Averna M; Arca M; Oliva F; Colivicchi F; Catapano A
    G Ital Cardiol (Rome); 2023 Jan; 24(1):5-10. PubMed ID: 36573504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and not treating with lipoprotein apheresis.
    Stefanutti C; Chan DC; Dip GZ; Watts GF
    J Clin Lipidol; 2024 May; ():. PubMed ID: 39054196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia.
    Cesaro A; Fimiani F; Gragnano F; Moscarella E; Schiavo A; Vergara A; Akioyamen L; D'Erasmo L; Averna M; Arca M; Calabrò P
    Heart Fail Clin; 2022 Jan; 18(1):177-188. PubMed ID: 34776078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.
    Srivastava RAK
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.